By Sandra G. Boodman, Washington Post, November 24, 2014
‘That’s it — I’m done,” Rachel Miller proclaimed, the sting of the neurologist’s judgment fresh as she recounted the just-concluded appointment to her husband. Whatever was wrong with her, Miller decided after that 2009 encounter, she was not willing to risk additional humiliation by seeing another doctor who might dismiss her problems as psychosomatic.
Research Letter by Gregory T. Whitman, MD; Robert W. Baloh, MD
Otonomy, Inc. (Nasdaq: OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, and Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, today announced that they have entered into an exclusive licensing agreement enabling Otonomy to utilize Ipsen's gacyclidine data in the development and registration of OTO-311.
VEDA Resource Library
Find a Vestibular Specialist
Help VEDA collect data on the vestibular patient experience.
Together we can advocate for actions that reduce the time it takes to diagnose a vestibular disorder.
Membership Changes Coming Soon!
VEDA will be rolling out a new membeship program in 2015. Current memberships will not be affected, but there will be lots of new ways to get involved. Stay tuned!